Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways

Cancer Letters

Volumn 326, Issue 2, 2012, Pages 135-142

  Jiang, Xue Jie ^a   Huang, Kai Kai ^a   Yang, Mo ^a,b   Qiao, Liang ^c   Wang, Qiang ^a   Ye, Jie Yu ^a   Zhou, Hong Sheng ^a   Yi, Zheng Shan ^a   Wu, Fu Qun ^a   Wang, Zhi Xiang ^a   Zhao, Qing Xia ^a   Meng, Fan Yi ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

AKT; Bortezomib; Leukemia; NF B; Panobinostat

Indexed keywords

BORTEZOMIB; CASPASE; DOXORUBICIN; HISTONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESEARCH; ENZYME ACTIVATION; ENZYME INHIBITION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REFRACTORY ANEMIA;

EID: 84866876804     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.030     Document Type: Article

References (51)

1. Tallman M.S., Gilliland D.G., Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 2005, 106:1154-1163.
2. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
3. Tsuruo T., Naito M., Tomida A., Fujita N., Mashima T., Sakamoto H., Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94:15-21.
4. McCubrey J.A., Steelman L.S., Franklin R.A., Abrams S.L., Chappell W.H., Wong E.W., Lehmann B.D., Terrian D.M., Basecke J., Stivala F., Libra M., Evangelisti C., Martelli A.M. Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv. Enzyme Regul. 2007, 47:64-103.
5. Sun Z.J., Chen G., Hu X., Zhang W., Liu Y., Zhu L.X., Zhou Q., Zhao Y.F. Activation of PI3K/Akt/IKK-α/NF-κB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis 2010, 15:850-863.
6. Panwalkar A., Verstovsek S., Giles F. Nuclear factor-KappaB modulation as a therapeutic approach in hematologic malignancies. Cancer 2004, 100:1578-1589.
7. Dos Santos C., Récher C., Demur C., Payrastre B. The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia. Bull. Cancer 2006, 93:445-447.
8. Dolcet X., Llobet D., Pallares J., Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005, 446:475-482.
9. Choi B.H., Kim C.G., Lim Y., Shin S.Y., Lee Y.H. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NFκB pathway. Cancer Lett. 2008, 259:111-118.
10. Pérez-Galán P., Roué G., Villamor N., Montserrat E., Campo E., Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107:257-264.
11. McCubrey J.A., Abrams S.L., Ligresti G., Misaghian N., Wong E.W., Steelman L.S., Bäsecke J., Troppmair J., Libra M., Nicoletti F., Molton S., McMahon M., Evangelisti C., Martelli A.M. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 2008, 22:2080-2090.
12. Tazzari P.L., Cappellini A., Ricci F., Evangelisti C., Papa V., Grafone T., Martinelli G., Conte R., Cocco L., McCubrey J.A., Martelli A.M. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007, 21:427-438.
13. Barattin R., Perrotton T., Trompier D., Lorendeau D., Pietro A.D., d'Hardemare Adu M., Baubichon-Cortay H. Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1. Bioorg. Med. Chem. 2010, 18:6265-6274.
14. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009, 280:233-241.
15. Vink J., Cloos J., Kaspers G.J. Proteasome inhibition as novel treatment strategy in leukaemia. Br. J. Haematol. 2006, 134:253-262.
16. Catley L., Weisberg E., Kiziltepe T., Tai Y.T., Hideshima T., Neri P., Tassone P., Atadja P., Chauhan D., Munshi N.C., Anderson K.C. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006, 108:3441-3449.
17. Geng L., Cuneo K.C., Fu A., Tu T., Atadja P.W., Hallahan D.E. Histone Deacetylase (HDAC) Inhibitor LBH589 increases duration of γ-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res. 2006, 66:11298-12304.
18. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., Sigua C., Sondarva G., Moscinski L., Atadja P., Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005, 105:1768-1776.
19. Giles F., Fischer T., Cortes J., Garcia-Manero G., Beck J., Ravandi F., Masson E., Rae P., Laird G., Sharma S., Kantarjian H., Dugan M., Albitar M., Bhalla K. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 2006, 12:4628-4635.
20. Landis-Piwowar K.R., Milacic V., Chen D., Yang H., Zhao Y., Chan T.H., Yan B., Dou Q.P. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. Drug Resist Updat. 2006, 9:263-273.
21. Horton T.M., Gannavarapu A., Blaney S.M., D'Argenio D.Z., Plon S.E., Berg S.L. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother. Pharmacol. 2006, 58:13-23.
22. Zhang Q.L., Wang L., Zhang Y.W., Jiang X.X., Yang F., Wu W.L., Janin A., Chen Z., Shen Z.X., Chen S.J., Zhao W.L. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 2009, 23:1507-1514.
23. Fuchs O., Provaznikova D., Marinov I., Kuzelova K., Spicka I. Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells. Cardiovasc. Hematol. Disord. Drug Targets 2009, 9:62-77.
24. Jagannath S., Dimopoulos M.A., Lonial S. Combined proteasome and histone deacetylase inhibition, a promising synergy for patients with relapsed/refractory multiple myeloma. Leuk. Res. 2010, 34:1111-1118.
25. Cai Y.X., Meng F.Y., Sun Q.X., Fu Y.B., Li L. In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells. Zhonghua Xue Ye Xue Za Zhi 2008, 29:737-740.
26. Perl A.E., Kasner M.T., Tsai D.E., Vogl D.T., Loren A.W., Schuster S.J., Porter D.L., Stadtmauer E.A., Goldstein S.C., Frey N.V., Nasta S.D., Hexner E.O., Dierov J.K., Swider C.R., Bagg A., Gewirtz A.M., Carroll M., Luger S.M. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin. Cancer Res. 2009, 15:6732-6739.
27. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
28. Ascione A., Cianfriglia M., Dupuis M.L., Mallano A., Sau A., Pellizzari Tregno F., Pezzola S., Caccuri A.M. The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells. Cancer Chemother. Pharmacol. 2009, 64:419-424.
29. Fakler M., Loeder S., Vogler M., Schneider K., Jeremias I., Debatin K.M., Fulda S. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009, 113:1710-1722.
30. Martelli A.M., Nyåkern M., Tabellini G., Bortul R., Tazzari P.L., Evangelisti C., Cocco L. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006, 20:911-928.
31. Ahn K.S., Sethi G., Aggarwal B.B. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem. Pharmacol. 2008, 75:907-913.
32. Bonhoure E., Pchejetski D., Aouali N., Morjani H., Levade T., Kohama T., Cuvillier O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 2006, 20:95-102.
33. Mahadevan D., List A.F. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004, 104:1940-1951.
34. Brunelle J.K., Ryan J., Yecies D., Opferman J.T., Letai A. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than Bcl-2-dependent counterparts. J. Cell Biol. 2009, 187:429-442.
35. Ikezoe T., Yang J., Nishioka C., Yokoyama A. P53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells. Int. J. Hematol. 2010, 91:69-77.
36. Eckelman B.P., Salvesen G.S., Scott F.L. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006, 7:988-994.
37. Schimmer A.D., Welsh K., Pinilla C., Wang Z., Krajewska M., Bonneau M.J., Pedersen I.M., Kitada S., Scott F.L., Bailly-Maitre B., Glinsky G., Scudiero D., Sausville E., Salvesen G., Nefzi A., Ostresh J.M., Houghten R.A., Reed J.C. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004, 5:25-35.
38. Sung K.W., Choi J., Hwang Y.K., Lee S.J., Kim H.J., Kim J.Y., Cho E.J., Yoo K.H., Koo H.H. Overexpression of X-linked inhibitor of apoptosis protein (XIAP) is an independent unfavorable prognostic factor in childhood de novo acute myeloid leukemia. J. Korean Med. Sci. 2009, 24:605-613.
39. Wang X., Wang C., Qin Y.W., Yan S.K., Gao Y.R. Simultaneous suppression of multidrug resistance and antiapoptotic cellular defense induces apoptosis in chemoresistant human acute myeloid leukemia cells. Leuk. Res. 2007, 31:989-994.
40. Carter B.Z., Mak D.H., Schober W.D., Koller E., Pinilla C., Vassilev L.T., Reed J.C., Andreeff M. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML. Blood 2010, 115:306-314.
41. Pei X.Y., Dai Y., Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 2004, 10:3839-3852.
42. +cells sensitive and resistant to STI571. Blood 2003, 102:3765-3774.
43. Yang M., Huang J., Pan H.Z., Jin J. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-κB pathways in human multiple myeloma cells. Int. J. Mol. Med. 2008, 22:489-496.
44. Matkovic K., Brugnoli F., Bertagnolo V., Banfic H., Visnjic D. The role of the nuclear Akt activation and Akt inhibitors in all-transretinoic acid-differentiated HL-60 cells. Leukemia 2006, 20:941-951.
45. Jenkins C., Hewamana S., Gilkes A., Neelakantan S., Crooks P., Mills K., Pepper C., Burnett A. Nuclear factor-κB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. Br. J. Haematol. 2008, 14:661-671.
46. Prince H.M., Bishton M.J., Johnstone R.W. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009, 5:601-612.
47. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2003, 2:151-163.
48. Kim H., Kim S.N., Park Y.S., Kim N.H., Han J.W., Lee H.Y., Kim Y.K. HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization. Int. J. Oncol. 2011, 38:807-812.
49. Matondo M., Bousquet-Dubouch M.P., Gallay N., Uttenweiler-Joseph S., Recher C., Payrastre B., Manenti S., Monsarrat B., Burlet-Schiltz O. Proteasome inhibitor-induced apoptosis in acute myeloid leukemia: a correlation with the proteasome status. Leuk. Res. 2010, 34:498-506.
50. Heider U., von Metzler I., Kaiser M., Rosche M., Sterz J., Rötzer S., Rademacher J., Jakob C., Fleissner C., Kuckelkorn U., Kloetzel P.M., Sezer O. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur. J. Haematol. 2008, 80:133-142.
51. Jagannath S., Dimopoulos M.A., Lonial S. Combined proteasome and histone deacetylase inhibition: a promising synergy for patients with relapsed/refractory multiple myeloma. Leuk. Res. 2010, 34:1111-1118.